Basic Information
| LncRNA/CircRNA Name | PCAT29 |
| Synonyms | PCAT29 |
| Region | GRCh38_15:69592200-69695750 |
| Ensemble | ENSG00000259641 |
| Refseq | NR_126437 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot etc. |
| Sample | cell line (DU145) |
| Expression Pattern | down-regulated |
| Function Description | Our data show that the expression of PCAT29 was reduced in prostate cancer tumors compared to paired perinormal prostate tissues. |
| Pubmed ID | 28467474 |
| Year | 2017 |
| Title | Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol |
External Links
| Links for PCAT29 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |